Antitrust Battle Ignites as Pfizer Obstructs Novo's $9 Billion Metsera Acquisition

Bitget App

Trade smarter

Bitget

News

Markets

Antitrust Battle Ignites as Pfizer Obstructs Novo's $9 Billion Metsera Acquisition

Bitget-RWA2025/11/06 08:30

By:Bitget-RWA

- Novo Nordisk's $9B Metsera acquisition faces Pfizer lawsuits alleging antitrust violations and breach of contract under U.S. antitrust laws. - Pfizer claims the deal delays GLP-1 competition and binds Metsera to restrictive covenants, while Novo dismisses allegations as "baseless" and confident in antitrust compliance. - Novo cuts $8B annual costs, launches Wegovy pill, and partners with Costco/Walmart to counter 9% market share loss amid U.S. pricing pressures and patent expirations. - The obesity drug

Novo Nordisk, the Danish pharmaceutical leader known for its best-selling weight-loss medications Wegovy and Ozempic, is facing a twofold challenge as it works to maintain its top position amid ongoing lawsuits and updated financial projections. The company’s planned $9 billion purchase of biotech company

Metsera

has come under heavy examination, with

Pfizer

initiating two legal actions that accuse Novo of anti-competitive behavior and violating contractual agreements, according to a

PharmExec article

. These lawsuits, which cite the Sherman and Clayton Acts, seek to prevent Novo’s acquisition and to uphold Pfizer’s initial $7.3 billion bid for Metsera, as detailed by

Seeking Alpha

Pfizer contends that

Novo

Nordisk’s deal structure is intended to postpone Metsera’s participation in the GLP-1 drug market, thereby limiting competition and safeguarding Novo’s market dominance, according to a

Yahoo News story

. The complaint alleges that Novo’s upfront payment of $6.5 billion to Metsera—prior to regulatory clearance—binds Metsera to restrictive terms that could impede its research and development. Novo, on the other hand, has called these accusations “without merit,” maintaining that it has followed the Pfizer merger agreement and is confident the deal meets antitrust standards, as reported by

Global Banking & Finance

. Metsera’s board has also dismissed Pfizer’s arguments, claiming Pfizer is trying to “use litigation to force a lower purchase price.”

This legal dispute highlights the enormous stakes in the obesity medication industry, where experts predict annual sales could climb to $150 billion in the near future. Novo’s intended acquisition of Metsera would strengthen its development pipeline with new therapies that could bring in $5 billion in revenue. At the same time, Pfizer’s strategy to enter this market depends on securing Metsera to advance its own weight-loss drugs, a key move as it faces patent losses and shrinking income from older medicines.

On the financial front,

Novo Nordisk

posted robust third-quarter numbers, with sales rising 15% and operating profit up 10% for the first nine months of 2025, according to its

Q3 2025 earnings highlights

. Still, the company has lowered its full-year outlook, citing stronger competition and mounting pricing challenges. It now anticipates sales growth of 8–11% (at constant exchange rates) and operating profit growth of 4–7%, a reduction from earlier estimates, as noted in a

BioSpace press release

. These changes reflect difficulties in the U.S. market, where compounded GLP-1 drugs and regulatory obstacles, such as price controls from the Inflation Reduction Act, are putting pressure on profits, according to

GuruFocus

To address these challenges, Novo is implementing an $8 billion annual cost-saving plan and reducing its global workforce by 9,000, as highlighted in its Q3 2025 earnings report. The company also revealed new product launches, including an oral version of Wegovy, and has formed partnerships with major retailers Costco and Walmart to broaden its market reach, according to an

earnings call transcript

. These initiatives are designed to recover from a 9% decline in Novo’s market share in the diabetes and obesity space over the past year, the company stated in its earnings call.

As the legal contest over Metsera continues, Novo Nordisk’s success will depend on how well it manages legal risks while driving innovation to stay ahead in this fast-changing industry.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

- Bitcoin faces a volatility squeeze near $100,000 as November 2025 approaches, with potential for dramatic price swings. - Galaxy Digital cuts 2025 BTC price target to $120,000, citing institutional outflows, whale distributions, and market corrections. - Technical indicators show compressed Bollinger Bands and extreme volatility levels, historically preceding major price moves. - Geopolitical risks and regulatory scrutiny contrast with JPMorgan's $165,000 2025 forecast, pending ETF inflows and Fed policy

Bitget-RWA•2025/11/06 09:38

Bitcoin Updates Today: Bitcoin Faces Volatility Compression: November's Critical $100k Battle

Starknet Allocates 100 Million STRK to Address DeFi’s Challenges in Scalability and Security

- Starknet allocates 100M STRK tokens to boost DeFi innovation, targeting scalability and security challenges through zero-knowledge infrastructure. - CeFi-DeFi convergence accelerates as platforms like SunPerp blend CEX usability with on-chain custody, surpassing $100M TVL despite recent sector vulnerabilities. - A $93M exploit at Stream Finance exposed DeFi risks, prompting urgent withdrawals and highlighting the need for robust risk frameworks in interconnected protocols. - AI integration in DeFi reshap

Bitget-RWA•2025/11/06 09:38

Starknet Allocates 100 Million STRK to Address DeFi’s Challenges in Scalability and Security

SBI and Chainlink Connect Traditional Finance and DeFi Through Secure Tokenized Compliance

- SBI Digital Markets adopts Chainlink CCIP to secure cross-chain transfers of tokenized assets like securities and real-world assets. - Integration uses CCIP's private transactions and ACE compliance engine to protect sensitive data while aligning with global regulations. - The partnership bridges TradFi and DeFi by enabling instant settlements and reducing cross-border transfer costs, supporting Asia-Pacific tokenized securities growth. - Industry experts highlight CCIP's role in addressing blockchain fr

Bitget-RWA•2025/11/06 09:38

SBI and Chainlink Connect Traditional Finance and DeFi Through Secure Tokenized Compliance

Robinhood’s Bold Move: Expanding Prediction Markets via Collaborations Instead of Building Platforms

- Robinhood's prediction markets generated $100M+ annualized revenue in Q3 2025, surpassing expectations through partnerships with Kalshi and Polymarket. - The segment's explosive growth stems from 2024 regulatory changes and sports betting legalization, with 2.5B contracts traded in October 2025. - CEO Tenev prioritizes user scale over vertical integration, leveraging 26M users to capture market share without developing proprietary platforms. - Q3 revenue hit $1.19B with $386M net profit, driving $130B ma

Bitget-RWA•2025/11/06 09:38